Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis.
about
Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy.
P2860
Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Effect of certolizumab pegol o ...... with axial spondyloarthritis.
@en
type
label
Effect of certolizumab pegol o ...... with axial spondyloarthritis.
@en
prefLabel
Effect of certolizumab pegol o ...... with axial spondyloarthritis.
@en
P2093
P2860
P50
P1433
P1476
Effect of certolizumab pegol o ...... with axial spondyloarthritis.
@en
P2093
Bengt Hoepken
Christian Stach
Jürgen Braun
Kay-Geert Hermann
Owen Davies
Pedro M Machado
Tommi Nurminen
Xenofon Baraliakos
P2860
P304
P356
10.1136/RMDOPEN-2017-000430
P577
2017-04-24T00:00:00Z